Please try another search
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Guy MacDonald | 62 | 2014 | Independent Chairman of the Board |
Steven C. Gilman | 70 | 2015 | Independent Director |
Philippe Tinmouth | 59 | 2019 | Independent Director |
Oliver Cornely | - | - | Member of Scientific Advisory Board |
Ann F. Hanham | 70 | 2008 | Independent Director |
Mahmoud Ghannoum | - | - | Member of Scientific Advisory Board |
David C. Hastings | 62 | 2015 | Independent Director |
Jack D. Sobel | - | - | Member of Scientific Advisory Board |
David W. Denning | - | - | Member of Scientific Advisory Board |
Luis Ostrosky-Zeichner | - | - | Member of Scientific Advisory Board |
Armando Anido | 65 | 2019 | Independent Director |
Barbara D. Alexander | - | - | Member of Scientific Advisory Board |
Paul Nyirjesy | - | - | Member of Scientific Advisory Board |
Peter G. Pappas | - | - | Member of Scientific Advisory Board |
David Gonzalez Angulo | 58 | 2015 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review